Evidence map›Paper›PMID 42824375›Full record

Observational studyFrontiers in immunology2026

Mapping the physical topology of the tumor immune microenvironment: macroscopic image fractals as surrogate markers for immune exclusion phenotype and treatment resistance in colorectal cancer liver metastases.

Guo Ziyi, Wentao Zhou, Kailin Zou

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guo ZiyiDepartment of Nuclear Medicine, Jinzhou Medical University, Jinzhou, China.
Wentao ZhouDepartment of Nuclear Medicine, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Kailin ZouDepartment of Nuclear Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The spatial tumor immune microenvironment (TIME) determines therapy response in colorectal cancer liver metastases (CRLM). To overcome biopsy sampling bias, this study investigates multimodal macroscopic image fractal dynamics to non-invasively map immune physical barriers and metabolic states, constructing a multi-scale immune-radiomics joint score (IRJS) for robust prognostic stratification and exploratory assessment of treatment resistance. Materials and methods: This dual-center observational study enrolled 270 CRLM patients with dual-modality imaging (contrast-enhanced magnetic resonance imaging, CE-MRI, 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography, Results: FD_MRI positively correlated with α-SMA Conclusion: Dual-modal fractal dynamics provide non-invasive surrogate markers for mechanical constraints and metabolic exhaustion in CRLM. The IRJS model enables robust spatiotemporal assessment of immune evasion, offering multidisciplinary teams a potential framework to explore non-invasive biopsy decisions, prognostic stratification, and provide exploratory insights into potential immunotherapy resistance.

Indexed as

Colorectal NeoplasmsDrug Resistance, NeoplasmLiver NeoplasmsTumor MicroenvironmentAgedFemaleFractalsHumansMagnetic Resonance ImagingMaleMiddle AgedPhenotypePositron Emission Tomography Computed TomographyPrognosisRadiomicscolorectal cancer liver metastasesexplainable artificial intelligencefractal dimensionimmune exclusion phenotypetreatment resistancetumor immune microenvironment

Identifiers

PMID42824375
PMCPMC13627372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.